Mykafungina Accordpharma (Micafungin)

Micafungin, the active ingredient in Mykafungina Accordpharma, is an echinocandin presented as an oral dosage form for oral use. It treats invasive candidiasis, esophageal candidiasis and candidemia in patients who need systemic antifungal therapy.

GNH USA supplies Mykafungina Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal used to treat systemic Candida infections.

- Invasive candidiasis: clears bloodstream and deep‑tissue Candida infection. - Esophageal candidiasis: resolves mucosal lesions and associated symptoms. - Candidemia: eradicates Candida species from the bloodstream.

Micafungin may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Elevated liver enzymes

Serious or Rare Side Effects: - Severe hepatic dysfunction - Hypersensitivity reactions including anaphylaxis - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing Micafungin, clinicians should consider several safety measures.

- Monitor liver function: obtain baseline and periodic liver‑function tests. - Assess renal function: adjust use in patients with significant renal impairment. - Evaluate for hypersensitivity: discontinue if severe allergic reactions occur. - Use caution in patients with pre‑existing severe liver disease. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Micafungin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inducers (e.g., rifampin) may markedly reduce micafungin exposure. - Co‑administration with cyclosporine or tacrolimus can increase their plasma concentrations, raising the risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Fluconazole may increase micafungin levels; monitor for toxicity. - Warfarin: observe INR closely as micafungin may affect anticoagulation. - Other azole antifungals: potential for additive hepatic effects; check liver enzymes regularly.